Gossamer Bio (GOSS) Q3 FY2026 earnings: revenue $38 million, up 189.1% on the year
Gossamer Bio, Inc. (GOSS) reported revenue of $38 million for Q3 FY2026, the quarter ended 30 September 2026, up 189.1% on the same quarter a year earlier. Net income was -$48 million, and diluted earnings per share $-7.36. The figures are the company's own, from the 10-Q it filed with the SEC on 10 November 2026.
Revenue
$38 million
+189.1% on the year · +316.0% on the quarter
Q4 FY2024Q3 FY2026
Operating margin
18.7%
-369.4% a year earlier
Q4 FY2024Q3 FY2026
Net income
-$48 million
Q4 FY2024Q3 FY2026
Diluted EPS
-$7.36
Q4 FY2024Q3 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 4 new.
Revenue rose on Chiesi termination: Revenue from contracts with collaborators was $38.4 million, against $13.3 million a year earlier. The company attributed the increase mainly to revenue recognized on the Chiesi termination.
Net loss near prior-year level: Net loss was $48.1 million, or $7.36 per share, against $48.2 million, or $16.92 per share, a year earlier. Weighted average basic shares were 6,530,004, against 2,849,768.
NDA submitted in September: The company submitted its first NDA, for seralutinib in PAH, to the FDA in September 2026.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
-29.6
-39.4
-36.2
Capital expenditure
0.0
0.0
0.0
Free cash flow
-29.6
-39.4
-36.2
Free cash flow margin
-77.0%
-426.8%
-272.1%
Cash from investing
15.9
42.7
17.0
-62.8%
-6.5%
Cash from financing
23.7
-3.1
1.9
+1,167.0%
Depreciation and amortisation
n/a
n/a
0.0
Share-based compensation
3.8
2.5
2.7
+53.9%
+42.2%
Diluted shares, weighted
7m
7m
5m
-0.7%
+43.2%
Shares outstanding at period end
6m
10m
5m
-37.4%
+32.2%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
-123
-94.0
-82.3
Debt
37.1
36.1
198
+2.8%
-81.3%
Operating lease liabilities
2.7
3.0
3.7
-8.9%
-27.2%
Other liabilities
147
132
89.2
+11.8%
+65.1%
Total liabilities and equity
64.3
76.9
209
-16.3%
-69.2%
Fixed assets
0.1
0.1
0.1
-7.3%
-27.1%
Investments
0.0
15.9
171
Cash and equivalents
51.2
41.1
8.9
+24.4%
+473.0%
Receivables
0.0
6.1
9.2
Other assets
13.1
13.7
19.3
-4.3%
-32.1%
Total assets
64.3
76.9
209
-16.3%
-69.2%
Questions
What was Gossamer Bio's revenue in Q3 FY2026?
Gossamer Bio (GOSS) reported revenue of $38 million for Q3 FY2026, the quarter ended 30 September 2026, up 189.1% on the same quarter a year earlier.
How much did Gossamer Bio earn in Q3 FY2026?
Net loss for Q3 FY2026 was $48 million, and the diluted loss per share $7.36.
When did Gossamer Bio report Q3 FY2026 results?
Gossamer Bio filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 10 November 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2026, filed 10 November 2026: the filing.